3‑Fluorophenmetrazine is a synthetic psychoactive compound belonging to the phenmetrazine class of substituted phenyl‑morpholine stimulants. It is the fluorinated analogue of phenmetrazine, in which a fluorine atom substitutes a hydrogen on the phenyl ring at the meta (3‑) position. The substance has been investigated primarily in the context of recreational drug use and as a research chemical; it has no approved medical applications.
Chemical Information
| Property | Data |
|---|---|
| IUPAC name | 3‑(3‑fluorophenyl)‑2‑methylmorpholine |
| Molecular formula | C₁₁H₁₄FNO |
| Molecular weight | ≈ 195.22 g·mol⁻¹ |
| CAS Registry Number | Not assigned (as of the latest available data) |
| SMILES | Fc1cccc(c1)C2CNCCO2C |
| Synonyms | 3‑F‑PM, 3‑Fluoro‑phenmetrazine |
The compound consists of a morpholine ring bearing a methyl substituent at the 2‑position and a 3‑fluorophenyl group attached at the 3‑position of the ring.
Pharmacology
- Mechanism of action: 3‑Fluorophenmetrazine acts as a releasing agent for the monoamine neurotransmitters dopamine (DA) and norepinephrine (NE). In vitro assays indicate it has modest activity at the serotonin transporter (SERT), but its primary stimulant effects are attributed to dopaminergic and noradrenergic release.
- Pharmacodynamics: The compound produces increased synaptic concentrations of DA and NE, leading to stimulant effects such as heightened alertness, euphoria, and increased locomotor activity.
- Pharmacokinetics: Specific data on absorption, distribution, metabolism, and excretion (ADME) are limited. It is presumed to undergo hepatic metabolism similar to phenmetrazine, with oxidative deamination and conjugation pathways, but detailed metabolic profiles have not been published in peer‑reviewed literature.
Legal Status
Regulatory status varies by jurisdiction. Because 3‑fluorophenmetrazine is a structural analogue of phenmetrazine—a Schedule II controlled substance in the United States and similarly controlled in many other countries—some jurisdictions may apply analogue drug legislation to prohibit its possession, manufacture, or distribution. As of the latest publicly available information, no specific national scheduling has been recorded for 3‑fluorophenmetrazine.
Research and Usage
- Research context: The compound has been listed in scientific and forensic reports concerning novel psychoactive substances (NPS) emerging in the recreational drug market. Analytical methods such as gas chromatography‑mass spectrometry (GC‑MS) and liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) have been developed to detect 3‑fluorophenmetrazine in seized materials and biological specimens.
- Recreational use: Online drug forums and harm‑reduction websites have described 3‑fluorophenmetrazine as a “designer stimulant” with effects comparable to other phenmetrazine analogues. Dosage ranges reported anecdotally are typically 10–30 mg taken orally, though potency can vary with purity and individual metabolism.
- Safety profile: Systematic toxicological data are lacking. Reported adverse effects include cardiovascular stimulation (elevated heart rate and blood pressure), insomnia, anxiety, and potential for dependence. The absence of controlled clinical studies precludes definitive conclusions about toxicity or long‑term health impacts.
References
- PsychonautWiki – “3‑Fluorophenmetrazine” entry (accessed 2024).
- EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) – Reports on novel psychoactive substances, 2023 edition.
- Scientific literature – In vitro transporter assays of phenmetrazine analogues (e.g., Journal of Pharmacology and Experimental Therapeutics, 2022).
Note: The above sources constitute the most reliable publicly available information on 3‑fluorophenmetrazine. Further peer‑reviewed studies are required to fully elucidate its pharmacology, toxicology, and legal classification.
